NeoGenomics, Inc. (NEO)

In the past six months, NeoGenomics reported strong third-quarter 2025 results and preliminary expectations for fourth-quarter 2025 revenue. The company launched RaDaR® ST and PanTracer™ LBx received Medicare coverage. NeoGenomics reported its first-quarter 2026 results, leading to upgrades from Leerink Partners and TD Cowen. Despite these positive developments, the stock price has experienced a decline.

While the overall oncology molecular diagnostics market is experiencing significant growth, there can be some seasonality in the diagnosis of certain cancer types. Historically, for cancers such as melanomas, prostate, breast, and thyroid cancer, there has been a decrease in the frequency of new cases diagnosed during the summer months and in December. This suggests that demand for NeoGenomics' diagnostic testing services for these specific cancer types might experience some seasonal fluctuations.

NeoGenomics, Inc. is a leading American clinical laboratory, pharma services, and information services company specializing in cancer genetics diagnostic testing, operating within the Healthcare sector and the Medical Diagnostics & Research industry. The company provides a comprehensive menu of oncology-focused testing services to various entities. Its major products and services include cancer genetics diagnostic testing, cytogenetics, FISH, flow cytometry, immunohistochemistry and anatomic pathology, molecular genetics and NGS, RaDaR® ST, PanTracer™ LBx and PanTracer Pro, pharma services division, and oncology data solutions.

NeoGenomics is headquartered in Fort Myers, Florida, and operates a network of CAP-accredited and CLIA-certified laboratories across the United States in Florida, California, North Carolina, Texas, and Arizona. Internationally, the company maintains CAP-accredited laboratories in Cambridge, United Kingdom, and previously had a headquarters in Rolle, Switzerland. NeoGenomics serves clients throughout the United States and Europe.

In the past year, NeoGenomics has faced a disclosed risk regarding test reliability and diagnostic errors, which could potentially threaten its reputation and lead to legal exposure. This risk was highlighted in a February 18, 2026 report, emphasizing the sensitivity of patients and healthcare providers to diagnostic accuracy in the industry.

NeoGenomics, Inc. has a diverse ownership structure, with 270 institutional owners and shareholders holding a total of 131,250,195 shares. Approximately 62.00% of the company's stock is owned by Institutional Investors, 0.82% by Insiders, and 37.18% by Public Companies and Individual Investors. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, and First Light Asset Management, LLC.